<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Venook, Alan P.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Outcomes Similar with BEV or CET Added to Induction CT for mCRC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-17</style></pages><abstract><style  face="normal" font="default" size="100%">First-line treatment for metastatic colorectal cancer (mCRC) is combination chemotherapy (CT) plus a monoclonal antibody (mAB). The Cetuximab and/or Bevacizumab Combined With Combination Chemo—therapy in Treating Patients With Metastatic Colorectal Cancer [CALGB/SWOG 80405; NCT00265850] study examined whether a strategy that blocked endothelial growth factor receptors with the mAB cetuximab (CET) or blocked vascular endothelial growth factors with the mAB bevacizumab (BEV) provided a greater improvement in the effectiveness of CT.</style></abstract><number><style face="normal" font="default" size="100%">22</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>